Cancer Biology and Therapeutics

Stewart Sell completed his graduation from University of Pittsburg. He was appointed as associate professor at University of California and became professor of pathology at University of Texas in the year 1997. In 2003 he became professor of pathology at University of Albany.

Cancer, carcinogenesis, and aging

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing geneenvironment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumours, soft-tissue sarcomas, and HPV-related cancers.  Additionally, Bioinformatics and Genomics

Anupam Bishayee is the Chair and Associate Professor of Pharmaceutical Sciences, American University of Health Sciences, Signal Hill, CA. His research focuses on elucidation of the cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer. His ongoing projects are funded by the National Institutes of Health as well as private pharmaceutical/biotechnological institutions. He has published more than 86 original research papers and review articles in high-impact, peer-reviewed journals, 9 book chapters, and presented over 25 papers at various national and international scientific meetings.

Cancer chemoprevention and chemotherapy by dietary agents and phytochemicals, chemoprevention of hepatocarcinogenesis and hepatocellular carcinoma, chemoprevention of mammary carcinogenesis and breast cancer resveratrol and cancer chemoprevention berry and cancer chemoprevention Oxidative stress, inflammation and cancer

Shiaw-Yih Lin has studied DNA damage response in cancer for 10+ years, during which time he has authored more than 40 peer-reviewed reports. He has served on the editorial boards for the World Journal of Clinical Oncology, American Journal of Cancer Research, Frontiers in Molecular and Cellular Oncology, World Journal of Translational Medicine, and Experimental Hematology & Oncology. He is a member of the International Scientific Advisory Board for International Institute of Anticancer Research, and he has served on numerous review committees for the NIH, DOD and Susan G. Komen for the Cure.

Endrometrial Cancer
Breast Cancer Dormancy
Functional and clinical analysis of Rak in breast cancer suppression

Liang Xu is a professor in the Department of Molecular Bioscience in University od Kansas. The goal of the proposed research is to establish nanovectors as a gene/miRNA delivery platform to develop novel molecular therapies targeting cancer stem cells. In summary he has a demonstrated record of successful and productive research projects relevant to the his research field and his expertise and experience have prepared him to go for invention of a new direction in cancer research.

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery.(Funded by multiple NIH and DOD grants). Molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. Exploring microRNAs as novel targets for cancer and cancer stem cells. Nanovectors targeting cancer cells for siRNA/miRNA-based novel cancer therapeutics. Nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Tumor cell invasion and metastasis, cancer cell metabolism, Cancer cells migrate

Tapan Bera received his M.S. and Ph.D. in Biochemistry from the Calcutta University, India. He completed his postdoctoral research training in the Cancer Research Laboratory, UC Berkeley and in the Laboratory of Molecular Biology, National Cancer Institute. Currently he held the Associate Scientist position at the National Cancer Institute, NIH, USA. His research objectives are focused mainly on to understand the molecular basis of cancer by identifying the genes involved in this process and translate that information to possible targeted therapy of cancer. He has discovered several very interesting and important genes whose expression is restricted to normal prostate and prostate cancer and are now being developed as therapeutic targets for the treatment of prostate cancer. He is author/co-author in more than 65 papers published in peer-reviewed journals.

Cancer biology and Immunotherapy

Yaguang Xi serves as an Assistant Professor of oncologic sciences at the Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA. In 2003, Dr. Xi earned his Ph.D. degree in cancer biology from the Peking University after he accomplished the medical training. His expertise covers molecular biology, cell biology, genomics, genetics, oncology, and bioinformatics. Currently, Dr. Xi focuses on characterizing micro-RNA biomarkers and validating their important roles in cancer development, tumor metastasis, chemotherapy, and prevention.

Cell biology, genomics, genetics, oncology

Reza Hakkak is Professor in the Department of Dietetics and Nutrition, University of Arkansas for Medical Sciences. He is nutritionist, Professor of Pediatrics in the College of Medicine, and Maternal Child Health in the College of Public Health.

Influence of diet and nutrition on cancer prevention, Obesity and Breast Cancer promotion, Animal modeling for Cancer Research, nutrition education, interactions of diet and drug metabolism, and alcohol as a risk factor for cancer development.

Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his Ph.D. Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer, mutant BRCA1 and BRCA2 genes profiles in ovarian cancer, proteomic profiling of metastatic genes of ovarian cancer, targeted molecular therapy for advanced epithelial ovarian cancer, minimally invasive surgery for gynecological cancer

Kenji Suzuki received his Ph.D. degree in information engineering from Nagoya University in 2001. From 1993 to 2001, he worked at Hitachi Medical Corporation and then Aichi Prefectural University as faculty. In 2001, he joined Department of Radiology at University of Chicago. Since 2006, he has been Assistant Professor of Radiology, Medical Physics and Cancer Research Center there. He has published 200 papers (including 75 peer-reviewed journal papers). He has been serving as the Editor-in-Chief and an Associate Editor of 12 leading international journals including Medical Physics, International Journal of Biomedical Imaging and Academic Radiology. He has received Paul Hodges Award, three RSNA Certificate of Merit Awards and Research Trainee Prize, Cancer Research Foundation Young Investigator Award, SPIE Honorable Mention Poster Award, IEEE Outstanding Member Award and Kurt Rossmann Excellence in Teaching Award. He has been a Senior Member of IEEE since 2004.

Kenji Suzuki areas of expertise are medical image analysis and quantitative imaging.

He was graduated from Tokyo College of Pharmacy. AZer completing his graduate study, he worked on radioactive tracer in drug metabolism as a research assistant at Physical pharmacy department. AZer obtained Ph.D. degree in Pharmaceutical sciences, he joined Dr. Lester Packer’s lab as a post‐doctoral fellow at University of California, Berkeley where he engaged in membrane bioenergetics research on halobacterial rhodopsin. In 1985, he obtained professor position and established radiopharmaceu8cal science lab at Niigata College of Pharmacy where free radical biology and molecular biological researches were developed. 2001, he engaged in establishing Food Science department in NUPALS and started food func8on study using an8oxidant tradi8onal oriental medicine formula as a food model. Current topics of his research are the food func8ons modula8ng DNA damage responses and aging, especially cell cycle checkpoint kinases and their applica8on in Complementary medicine in Cancer treatment. He published more than 150 papers in peer reviewed journal. He served as reviewer, editor of several scien8fic journals and for other social events. He has been chairing Interna8onal Niigata Symposium on Diet and Health since 2004.

Food functions modulating DNA damage responses and aging, especially cell cycle checkpoint kinases and their application in Complementary medicine in Cancer treatment.

Karol Sikora is Chief Medical Officer of Proton Partners International. He was the founder of Cancer Partners UK which has created UK’s largest independent UK cancer network with private equity. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and a Fellow of Corpus Christi College, Cambridge. He has published over 300 papers and written or edited 20 books including Treatment of Cancer - the standard British postgraduate textbook, now in its sixth edition. His new book for patients The street-wise patient’s guide to cancer survival has just been published.

Integrated Medicine, Medical Oncology, Gene Therapy and Cancer Strategy, Radiation Oncology, Alternative Medicine

Ken H. Young, MD PhD is a Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. He was Medical Director of Hematology at the University of Wisconsin School of Medicine and University East & West Clinic Laboratories, overseeing the laboratories at the University of Wisconin Hospital and Clinics Core Laboratory. He received his PhD from University of Lund School of Medicine and completed his MD training from Oregon Health Science University. He is board certified in Anatomic and Clinical Pathology and Hematopathology.

His interests are to characterize molecular defects in patients with leukemia and lymphoma by using gene expression profiling, immunophenotypic method, methylation-microRNA-CGH arrays and current NGS molecular technologies with particular interest in tumor suppressor genes, oncogenes, p53 and NF-kB pathways. He has worked extensively on molecular diagnostics for human cancer and has obtained several novel discoveries valuable to predict treatment response, clinical outcome and survival in cancer patients.

Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. He is on staff at Harvard TH Chan School of Public Health and Angiogenesis Foundation, both in Boston. He is also on faculty at University College London. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Nature/Springer book on breast cancer to be published in 2017 and Editor-in-Chief of the Journal of Bioequivalence and Bioavailability. He is a founder and on the Board of Directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer.

Cancer research, Charged particle optics, Early detection of cancer and delayed detection of cancer.

Prof. Dr. Jan Jacques Michiels Multidisciplinairy Internist Blood Coagulation & Vascular Medicine Center, CEO and Founder of Goodheart Institute in Nature Medicine & Health, Founder and Editor in Chief World Journal of Vascular Medicine: WJVM, Editor in chief Journal of Hematology and Thromboembolic Diseases, Editor of World Journal of Hematology: WJH. Senior Scientific Advisor European Leukemia-Net MPN, Mannheim, European Community, Brussels, Visiting professor Blood & Coagulation Disorders Depts of Hematology of the University Hospital Antwerp, Belgium, University Brno, Czech Republic and Colentina University Hospital, Bucharest, Romania. Prof. Dr. Jan Jacques Michiels is Consultant Professor Bloodcoagulation and Co-Founder of the Hememostasis Research Unit and Von Willebrand Research Laboratory, University Hospital Antwerp, Belgium. Founder International Collaboration and Research in MPN: ICAR; MPN within the European Leukemia-Network: ELN. He is a CoFounder of the Central European Vascular. He is Expert member Leukemia Net, Mannheim, Gernamy (Chair & Founder ELN, Professor Hehlmann, Mannheim). Founder International Collaborations & Academic Research on Von Willebranf Factor and Von Willebrand Disease: ICAR:VWF-VDW. Prof. Dr. Jan Jacques Michiels served as Guest Editor of many of the International Journals in Hematology, Hemostasis, Thrombosis and Vascular Medicine.

Leukemia, Hematology and Thromboembolic Diseases, Haemostasis, Bool & Coagulation Disorders.

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has an H index of 57, 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

Cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology.

Dianzheng Zhang has completed his PhD from University of Arizona and Postdoctoral studies from Baylor College of Medicine. He assumed an Assistant Professor position at PCOM in 2006 and promoted to an Associate Professor in 2011. He has published more than 40 papers in reputed journals and has served as a chairman for multiple international conferences.

Hematology

Dr. Bonnie Labdi earned her Doctor of Pharmacy degree from the University of Houston College Of Pharmacy in May of 2002. She completed two years of post-graduate residency through the University of Texas and Scott & White Hospital in June of 2004. She began working at the University of Texas M.D. Anderson Cancer Center in 2004 as a Clinical Pharmacy Specialist, focusing on the areas of hematologic malignancies, specifically lymphoma and myeloma. She remained there for over 6 years before accepting a clinical management position at a two-hospital health system located in Beaumont, Texas. As a clinical manager, she sat on many institutional committees, utilizing her leadership skills and experience in the areas of patient safety, hospital accreditation, and health care management. Most recently, she accepted a clinical specialist position at Memorial Hermann Hospital in Houston, Texas. Her primary areas of focus are in the areas of thoracic and head and neck medical oncology. She sees patients daily in clinic, working in collaboration with oncologists to formulate individualized treatment plans. Besides oncology, Dr. Labdi remains interested and active in the areas of supportive care, patient safety and quality improvement. She serves on several boards and committees of both national and international professional organizations, and is currently serving in her second year as Chairperson of the Publications Committee for the Hematology Oncology Pharmacists Association (HOPA). She has authored a book chapter and several peer-reviewed articles in the fields of oncology and supportive care. She most recently presented 3 talks at the Indo-Global Medical Summit & Expo in Hyderabad, India. She also presented a poster at the most recent World Conference on Lung Cancer annual meeting.

Oncology, Supportive care, Patient safety and Quality Improvement.

Olfat M Hendy completed her MD at the age of 35 years from Clinical pathology department, Menoufia Faclty of Medicine, Menoufia University, Egypt - and become professor of hematology & immunology at the same univerisity at 2009. She is the head of hematology unit at National Liver Institute- Menoufia University, Egypt. She has published more than 28 papers in reputed journals and has been serving as an editorial board member of repute. She was an supervisor on more than 32 MD and master thesis, and discussed more than 32 thesis. She is a membership in about 4 medical societies.

Clinical pathology, Hematology, Hematologic Disorders

Dr. Omar A. Fahmy is a professor of medicine & clinical hematology, Cairo University, where he graduated in 1985. He got his residency at the same institution in the department of medicine, clinical hematology unit, under the supervision of Professor Alaa El-Zayat, the founder of clinical hematology at Cairo University. Prof. Fahmy was honored the title of "The ideal doctor" in 1992 at the annual celebration of the Egyptian medical syndicate. In 1994, he was elected to receive a short post doctoral BMT training course at "Pitie – Salpetriere" hospital, Paris, France, under the supervision of professor JL Binet, the head of the hematology & BMT unit. Shortly afterwards, in 1995, Prof. Fahmy spent 12 months, as a research scholar, at the department of hematology & BMT, Case Western Reserve University, Cleveland, Ohio, USA. During his tenure, he mastered the art of BMT under the supervision of professor Stanton Gerson, the head of the department, & Prof. Hillard Lazarus, the director of the BMT program and the chairman of the ECOG-BMT committee. Currently, Dr. Fahmy is a member of the Lymphoma committee of the MENA region for the NCCN guidelines modifications. In addition, he is a hematology and BMT consultant in several Egyptian centers. He is a member of many professional societies including: the EHOG (Egyptian Hemato-Oncology Group), American Society of Hematology & American Society for Blood and Marrow Transplantation. His main interest is in the field of hematopoietic stem cell transplantation, and published more than 40 articles in that domain in several national and international journals.

Hematology, Hematopoietic Stem Cell Transplantation,

Dr. Nabil Mohie Abdel-Hamid is Professor of Cancer Biology at Department of Biochemistry, Ex- and First Dean and Founder of Faculty of Pharmacy, Kafrelsheikh University, Egypt. Professor Nabil Mohie Abdel-Hamid has many national and international Memberships like Member of The Higher Consulting Organization of Egyptian Scientists Council, Deputy of Director of The Egyptian Association of Cancer Research, member in: The Arab Evaluators for Scientific Degree Promotions and member in The Egyptian Evaluators for Scientific Degree Promotions.

Cancer Biology, Principal Instructor and interested in Hepatocellular Carcinoma Research (Both Early Detection, Looking for New Sensitive and Specific Markers and Therapeutic Perusal), as New Trends in Management of Hepatocellular Carcinoma, Including Chemo and Radio Sensitization to Cancer Therapy.

Professor Dass obtained his B App Sci (Hons) and PhD from Charles Sturt University, Australia. Prof. Dass has 22 years of basic and applied research in cancer. He has worked on big pharma projects (Amgen, Novartis, Glaxo-Wellcome, Johnson & Johnson). He has published in Nature Medicine, Journal of the National Cancer Institute, Journal of Controlled Release and Biomaterials. Prof. Dass has published 147 papers to date, 165 conference presentations, a h-index of 33, with total number of citations for his papers at ~3400. He has also reviewed original research papers in New England Journal of Medicine, Lancet and Nature Communications.

Professor Dass and his team are looking into the drug doxorubicin, which is used mainly to treat bone tumours, but can cause a number of side-effects in patients. This research is studying ways that the drug can be administered from an aggressive “hitting it on its head” approach to a gentler alternative that would reduce side-effects and still kill the tumour.

Charles J. Malemud received his Ph.D. from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. Since 1977, Dr. Malemud has been a member of the faculty at Case Western Reserve University School of Medicine where he is presently Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory. He has published more than 190 papers, chapters and reviews primarily in the field of chondrocyte biology. Professor Malemud is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology.

Charles J. Malemud research interests include Biology of the Musculoskeletal System, Intracellular Signal Transduction Pathways, Inflammation, Pro-inflammatory, Anti-Inflammatory & Anabolic Cytokines Apoptosis, Matrix, Metalloproteinases, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia and Autoimmune Disorders

Dr. Jun Li has received his M.D. from Sun Yat-sen University and his Ph.D. and postdoctoral training from University of Alabama at Birmingham (UAB). He focuses on developing novel therapies for autoimmune diseases including rheumatoid arthritis. Dr. Li is currently an Instructor of Medicine at UAB.

Jun Li major research interests include targeting M1 inflammatory macrophages in RA, determining the pathogenic roles of fucosylation in RA, and identifying the bidirectional interaction between macrophages and T cells in RA. Dr. Li’s work is supported by an Arthritis Foundation Post-doctoral Fellowship Award.

Dr Wim B van den Berg was born in 1950 and completed his studies in biochemistry, with sub-specialization in pharmacology and pathology at the free university in Amsterdam. Following his PhD in exp Pathology he moved to Nijmegen and started the Rheumatology research lab and advanced therapeutics in 1979. The research focuses on mechanisms of chronicity and joint destruction in arthritis and osteoarthritis, with an emphasis on cytokines and growth factors, such as IL-1, IL-17 and TGFb. Major expertise is developed in murine RA and OA models, including transgenic mice, adenoviral gene transfer and advanced therapeutics. He received the OARSI basic science award and the Federa award in 2001 and the Dutch rheumatology medal in 2002. In 2011 he received the IAIS (Int association of inflammation societies) life time achievement award.He published over 400 international papers, is deputy editor for basic science of Osteoarthritis and Cartilage, a board member of OARSI and a member of the editorial board of major arthritis journals.

Wim B van den Berg Research interests are focused on the role of cytokines and growth factors in chronicity of joint inflammation and mechanisms of destruction of cartilage and bone. Major expertise is in the development of murine models for arthritis and osteoarthritis and in the translation of experimental findings to advanced therapeutic modalities, including gene therapy.

Snezana Tomasevic Todorovic has completed her M.S. in 2001 year and PhD in 2009 year at Faculty of Medicine, University of Novi Sad, Serbia. She is an Assistant Professor at the Faculty of Medicine, Basic health care professional studies, Basic studies of rehabilitation and special education, Basic studies of Physiotherapy School of Medicine, University of Novi Sad. Since 2002, she has been working as physiatrist and rheumatologist, and a specialist of quantum medicine in the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina, Serbia. She has published more than 35 peer reviewed articles. Currently, she holds the position of vice-president of Serbian Association of Physiatrists, President of the Section of Physical Medicine and Rehabilitation Physicians of Vojvodina, Serbian Medical Society, and is a member of the Rheumatology Association of Serbia as well.

Snezana Tomasevic research interests include Rheumatic Diseases & Rheumatoid Arthritis Arthritis

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer

cancer research, charged particle optics, early detection of cancer and delayed detection of cancer

Dr. Chen is an Associate Professor at the Beckman Research Institute, City of Hope. Dr. Chen received his Ph.D. in Molecular Biology at the University of Alabama at Birmingham in 1999, and completed his postdoctoral training in Cancer Biology at Johns Hopkins University in 2005. Dr. Chen’s research covers epigenetic mechanisms of tumorigenesis, gene regulation by DNA methylation and histone modifications, animal models of cancer, and stem cells. Dr. Chen’s current research is on functions of sirtuin deacetylases in aging and cancer drug resistance, in particular, in the area involving hematopoietic stem cells and leukemia stem cells

Epigenetics, Cancer, Aging and Stem Cells

Dr. Sell is a board certified pathologist and immunologist. He has published over 400 papers and 12 books. His paper with Barry Pierce (Lab. Invest. 70:6-21, 1994.) was selected as an AACR scientific landmark. Among his findings are: development of delayed hypersensitivity before antibody formation (1959). the role of the thymus in development of immune competence (1964); first identification of immunoglobulin on the surface of B cells (1965; Current contents citation classic, 1984); classification of immunopathological reactions (1971); development of a radioimmunoassay for alphafetoprotein (1972); identification of liver stem cells during chemical hepatocarcinogenesis and in response to injury (1972-94); role of endocytosis in activation of B cells (1974); recognition that the chancre of syphilis is a delayed hypersensitivity reaction (1979); role of mGSTA3 in detoxification of aflatoxin (2004); and characterization of breast cancer stem cells (2012)

Cancer: To determine how bone marrow derived mesenchymal stem cells influence the development of cancers in other tissues. Cancer: To block proliferation of breast cancer stem cells by small molecular inhibitors or inhibitory RNA. This is a critical step to preventing re-growth of breast cancer after chemotherapy or radiation therapy. Carcinogenesis: To study the metabolism of aflatoxin and development of liver cancer in mice lacking glutathionine-S-transferase. Aging: To compare the ability of young vs. old bone marrow derived stem cells to reconstitute and provide long term survival after lethal irradiation and transplantation, and the ability of wild-type bone marrow to prolong life of early aging mice.

Bradford has a PhD in Medical Biochemistry- Oncology from the Roswell Park Cancer Institute, Division of SUNY at Buffalo School of Medical and Biomedical Sciences. She is the inventor of the various patents that AccuTheranostics holds. She was awarded the Award for Excellence in Research from the American Federation for Clinical Research, has authored many scientific papers and book chapters, and been an invited speaker at various international scientific meetings. Dr. Bradford is a member of many major professional cancer organizations including, ASCO, AACR and AAAS. As Chief Scientific Officer, Dr. Bradford guides the day-to-day research directives as well as the clinical laboratory operations.

President, CSO and Founder
AccuTheranostics, Inc.,USA

Bishayee is the Chair and Associate Professor of Pharmaceutical Sciences, American University of Health Sciences, Signal Hill, CA. Dr. Bishayee’s research focuses on elucidation of the cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer. The ongoing projects of Dr. Bishayee are funded by the National Institutes of Health as well as private pharmaceutical/biotechnological institutions. Dr. Bishayee has published more than 86 original research papers and review articles in high-impact, peer-reviewed journals, 9 book chapters, and presented over 25 papers at various national and international scientific meetings.

Assistant Dean and Chair
Associate Professor of Pharmaceutical Sciences
American University of Health Sciences
Signal Hill, USA

Professor Shiaw-Yih Lin has studied DNA damage response in cancer for 10+ years, during which time he has authored more than 40 peer-reviewed reports. He has served on the editorial boards for the World Journal of Clinical Oncology, American Journal of Cancer Research, Frontiers in Molecular and Cellular Oncology, World Journal of Translational Medicine, and Experimental Hematology & Oncology. Dr. Lin is a member of the International Scientific Advisory Board for International Institute of Anticancer Research, and he has served on numerous review committees for the NIH, DOD and Susan G. Komenfor the Cure.

DNA damage checkpoint and DNA repair
Genetic and chemical screens
Cancer stem cells
Cancer gene signatures

Dr. Lu’s work is to delineate the mechanisms of cellular signaling regulation in cancer cell metabolism, proliferation, migration and metastasis. His laboratory focuses on three areas: understanding how cancer advances by altering cancer cell metabolism; understanding how cancer cells migrate, invade and metastasize, and understanding how cancer progresses by promoting cell survival. He is an associate editor of Chinese Journal of Cancer and an editorial board member of other 8 journals including Cell Research and Neuro-Oncology

Tumor cell invasion and metastasis, cancer cell metabolism

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971).Dr. Yamaguchi is serving as editors and editorial board members of reputed 24 international Journals. He received many honor and awards.

cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis.

Dr. Salem Chouaib completed his undergraduate studies at the university of Pierre and Marie Curie (Paris VI) at Pasteur Institute. He received his Doctorat es-sciences (Ph.D.) in immunology, (laboratory of Jean Dausset, Nobel prize in medicine) in 1983 from the same university. He then joined the Memorial Sloan Kettering Cancer Center in New York where he undertook a post-doctoral training in Human Immnogenetics Laboratory. In 1986, he was appointed as research associate at the French National Institute of Health and Biomedical Research (INSERM) and joined the tumor biology department at the Institut Gustave Roussy. At present he is research director and is heading the INSERM research unit 753 (Human Cancer Immunology and Immunotherapy). Dr Chouaib’s laboratory currently focuses on the investigation of the functional cross talk between cytotoxic cells and tumor targets in the context of tumor microenvironment complexity and plasticity. Dr Chouaib research was constantly directed at impulsing the transfer of fundamental concepts in clinical application in particular in the field of cancer vaccine and cancer immunotherapy. He was awarded the cancer research prize of the French ligue against cancer in 1992 and in 2004 the presidential prize in biotechnology. He is lecturing tumor immunology for the PhD programs at the University Paris Sud. His research resulted in more than 220 scientific articles and several reviews in the field of human immunology and tumor biology as well as in editorship for contribution to several books. Furthermore he is guest lecturer at different universities. He is ad hoc referee for numerous journals and scientific foundations. He is a member of various professional associations and is scientific advisor and consultant in many scientific institutions.

Cell-mediated cytotoxicity, tumor microenvironment, immunology and immunotherapy of cancer.

Dr. Siddiqui earned his BSc and MSc degrees in Biochemistry from the University of Karachi, in Karachi, Pakistan. He obtained his PhD from the Australian National University in Canberra, Australia. While obtaining his PhD, he investigated the metabolic basis of cancer cachexia under the supervision of Professor John F. Williams, who is famous for his pioneer research on the pentose phosphate pathway. Dr. Siddiqui served as a postdoctoral fellow at Massey University in Palmerton North, New Zealand in the laboratory of Dr. Stuart McCutcheon (currently Vice Chancellor of Auckland University in New Zealand). Dr. Siddiqui immigrated to America in 1989 and worked as a Howard Hughes fellowship at Vanderbilt University Medical Center in Nashville with Dr. John Exton. Dr. Siddiqui began his work as a researcher at Methodist Hospital in 1993 in the Bone Marrow Transplant Research Laboratory. He established his independent research laboratory in 1999 and is presently the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at the Methodist Research Institute. Dr. Siddiqui also has adjunct appointments in the Department of Biology, Indiana University-Purdue University and the Department of Medicine, Indiana University Medical School, Indianapolis. Dr. Siddiqui has received funding from the National Cancer Center (NIH), American Heart Association, Showalter Foundation, Abbott Pharmaceuticals, and Baxter Nutrition.

Dr. Siddiqui´s research interests are in the area of cancer, inflammation, and cardiovascular diseases. His research emphasis is on the synergistic modulation of breast cancer progression by combination of nutrients and drugs with omega-3 fatty acids.

Professor Ivan Gout graduated as an MD at Lviv Medical University (Ukraine) in 1983. He obtained his doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. In 1998, he started his own group at the Ludwig Institute for Cancer Research, focussing on the regulation of growth via the S6 kinase pathway. Since 2003, he has been a Professor in this Department, where he has an active research group working on signal transduction via the mTOR/S6K pathway in normal and cancer cells.

Cell signalling through phospholipases, kinases and G-proteins during differentiation and secretion, Cellular mechanisms underlying neurodegeneration.

Samir A. Farghaly is Physician / Scientist and national and international expert in Obstetrics and Gynecology – faculty member at the Medical College of Cornell University, and the New York Presbyterian Hospital/ Cornell University Medical Center, New York, NY – USA. He received his M.D degree from University College, London University and his PhD degree in molecular biology from London University. He was affiliated with Columbia University College of Physicians and surgeons/ Columbia University medical center, New York, NY. He received several national and international clinical and research awards. He has been an invited speaker in several national and international conferences on Women’s health, Molecular genetic of female cancers, Gynecological cancer and Oncology. He is a member of several national and international societies, organizations, foundations of Women health and Cancer. He is an editor, member of editorial boards, editorial advisory boards and reviewers of several medical journals of Cancer Science & Therapy, Gynecology, Gynecological Cancer, Genomics, Clinical & Experimental Obstetrics and Gynecology, and Oncology. He has published 78 articles in reputed peer review journals. He has written several books chapters, and is an editor of (2) books in Obstetrics and Gynecology, published in Feb. 2012, and the third book to be published in June 2013.

Obstetrics and Gynecology
Cornell University
USA